Agoraphobia Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The agoraphobia treatment market size is expected to increase from USD 2.34 billion in 2025 to USD 2.51 billion in 2026 and reach USD 3.58 billion by 2031, growing at a CAGR of 7.35% over 2026-2031. This report is Segmented by Treatment Modality (Psychotherapy, Pharmacotherapy, and More), Pharmacotherapy Class (SSRIs, Snris, and More), Route of Administration (Oral, Intranasal, Other), Care Setting (Outpatient Psychiatric Clinics, and More), Distribution Channel (Hospital Pharmacies, and More), & Geography (North America, Europe, and More). Market Forecasts are Provided in Terms of Value (USD).

Global Agoraphobia Treatment Market Trends and Insights

Increasing Diagnosis and Treatment-Seeking for Agoraphobia and Panic Disorder

The global burden of anxiety disorders has increased faster than many care systems can absorb. The 2026 Global Burden of Disease analysis reported 1.17 billion prevalent mental disorder cases in 2023, 95.5% higher than the 1990 count. The World Health Organization estimates that 4.4% of the global population lives with an anxiety disorder, while only 1 in 4 affected people receive treatment. In the United States, panic disorder affects 2.7% of adults in a given year and 4.7% over their lifetime. China announced a 2025-2027 plan to expand outpatient mental and sleep disorder services across prefecture-level cities. The Agoraphobia treatment market benefits when health systems identify people with existing symptoms and route them into formal treatment, rather than from changes in disease prevalence.

Guideline-Supported Adoption of CBT, Exposure Therapy, and SSRIs

Clinical guidelines support cognitive behavioral therapy, exposure therapy, SSRIs, and SNRIs for panic disorder with agoraphobia. The WFSBP guideline identifies SSRIs and SNRIs as first-line pharmacological options and cognitive behavioral therapy as the first-line psychotherapy. Germany’s DGPPN guidance recommends citalopram, escitalopram, paroxetine, sertraline, and venlafaxine as first-line options for panic disorder and agoraphobia. A 2025 review of Brazilian Psychiatric Association guidance identified high-grade evidence for SSRIs and SNRIs, while tricyclic antidepressants had moderate evidence due to adverse-event concerns. These aligned recommendations support more consistent prescribing, strengthen the role of pharmacotherapy alongside psychotherapy, and shift treatment patterns away from long-term benzodiazepine use toward established SSRI and SNRI therapies within the Agoraphobia treatment market.

Mental-Health Stigma and Delayed Presentation

Stigma delays when many people seek mental health care. In Japan, insurance-covered cognitive behavioral therapy reached only 0.14% of the country’s 6.03 million psychiatric patients in fiscal year 2024. The same study identified a 375-fold difference in utilization between the highest-performing and lowest-performing prefectures. These figures show that insurance coverage alone does not ensure broad use of psychotherapy.

Other drivers and restraints analyzed in the detailed report include:

• Digital CBT, Telepsychiatry, and Virtual Reality Exposure Delivery
• Homebound Patient Demand for Care Delivered Outside Traditional Clinics
• Limited Access, Reimbursement Gaps, and Out-of-Pocket Burden

Segment Analysis

Pharmacotherapy is expected to account for 52.66% of revenue in 2025, making it the largest component of the agoraphobia treatment market share. This leadership reflects strong evidence supporting SSRIs and SNRIs as scalable first-line options for panic disorder with agoraphobia. Combination and adjunctive treatment is forecast to grow at an 8.15% CAGR through 2031. WFSBP guidance places cognitive behavioral therapy alongside first-line drug treatments for anxiety disorders, while German clinical guidance supports SSRI and SNRI use for panic disorder and agoraphobia.

Digital treatment formats can improve access for patients who cannot receive in-person psychotherapy. A 2025 review found that therapist-guided digital cognitive behavioral therapy delivered significant effects in panic disorder and agoraphobia, with stronger adherence than unguided programs. This supports care models that combine clinician oversight, pharmacotherapy for symptom stabilization, and exposure-based therapy to address avoidance patterns. Reimbursement for digital services can support broader adoption in routine care.

SSRIs are expected to account for 58.76% of pharmacotherapy revenue in 2025 and remain widely used for panic disorder with agoraphobia due to established regulatory approvals and clinical guideline support. SNRIs are forecast to grow at a 9.80% CAGR through 2031. Clinicians use venlafaxine and duloxetine when patients do not achieve adequate results with SSRIs or present with mixed anxiety and depressive symptoms. The WFSBP guideline supports SNRIs as first-line pharmacological options for anxiety disorders, and German guidance identifies venlafaxine as a first-line treatment option.

Tricyclic antidepressants and benzodiazepines play a smaller role because safety concerns can limit use. The 2024 Brazilian guideline review gave SSRIs and SNRIs high evidence ratings, while tricyclic antidepressants received moderate ratings due to adverse-event risks. A 2025 review found that the FDA approved only two new anxiety-disorder medicines from 2008 through 2024, keeping established drug classes central to the agoraphobia treatment market. Buspirone, hydroxyzine, and pregabalin remain adjunctive options for patients who cannot tolerate antidepressants or receive treatment in primary care.

Complete Report Scope:

• By Treatment Modality
  • Psychotherapy
  • Pharmacotherapy
  • Combination and Adjunctive Treatment
• By Pharmacotherapy Class
  • Selective Serotonin Reuptake Inhibitors
  • Serotonin-Norepinephrine Reuptake Inhibitors
  • Tricyclic Antidepressants
  • Benzodiazepines
  • Other Anti-Anxiety Medicines
• By Route of Administration
  • Oral
  • Intranasal
  • Other Routes of Administration
• By Care Setting
  • Outpatient Psychiatric Clinics
  • Hospitals and Specialty Mental-Health Centers
  • Primary-Care Practices
  • Digital and Virtual Care Providers
  • Academic and Research Institutes
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Specialty Pharmacies
  • Direct-to-Patient Digital Channels
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 40.45% of global revenue in 2025, the largest regional revenue share. The United States supported regional demand through higher diagnosis rates, private coverage for medicines and outpatient psychotherapy, and FDA regulatory activity. The National Institute of Mental Health reported that 2.7% of U.S. adults had panic disorder in the past year. CMS reimbursement changes in 2025 improved the payment pathway for FDA-cleared digital mental health treatments. Canada and Mexico contributed revenue, although specialist shortages and public-system wait times left unmet need, while the regional system combined branded medicines, generics, digital services, and growing interest in intranasal psychiatric delivery.

Europe is the second-largest regional contributor, led by Germany, the United Kingdom, France, Italy, and Spain. Germany has a developed framework for evidence-based pharmacotherapy and reimbursed digital care for panic disorder and agoraphobia. The United Kingdom’s NICE guideline identifies SSRIs as the preferred pharmacological option for panic disorder with or without agoraphobia and supports cognitive behavioral therapy. France updated its standards for serious anxiety disorders in January 2025 and maintained eligibility criteria for SSRI and SNRI reimbursement. Spain, Italy, and other European markets are supported by awareness programs, public investment in mental health care, and a clearer pathway for prescribed digital services in the Agoraphobia treatment market.

Asia-Pacific is forecast to grow at an 8.58% CAGR through 2031, the fastest regional rate in the Agoraphobia treatment market. Efforts to address underdiagnosis, expand mental health infrastructure, and improve access to generic SSRIs and SNRIs support growth. Japan allocated 8.8% of its health budget to mental health in the supplied research, but insurance-covered cognitive behavioral therapy reached only 0.14% of 6.03 million psychiatric patients in fiscal year 2023. Australia’s Pharmaceutical Benefits Scheme subsidizes SSRIs and SNRIs, while South Korea’s digital therapeutics reimbursement framework was still developing through mid-2026. The Middle East and Africa and South America remained smaller markets due to workforce, insurance, and stigma-related barriers.

List of Companies Covered in this Report:

• Abbvie
• AstraZeneca
• Aurobindo Pharma
• Bristol-Myers Squibb
• Dr. Reddy’s Laboratories
• Eli Lilly and Company
• Freespira, Inc.
• GlaxoSmithKline
• H. Lundbeck
• Hikma Pharmaceuticals
• Johnson & Johnson
• Limbix Health, Inc.
• Lupin
• Neurocrine Biosciences
• Novartis
• Otsuka
• Pfizer
• Sun Pharmaceuticals Industries
• Takeda Pharmaceuticals
• Teva Pharmaceutical Industries
• Viatris
• Zydus Lifesciences Limited

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support